Kairos Pharma announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) combined with apalutamide in patients with metastatic castration-resistant prostate cancer. The analysis showed a statistically significant improvement in progression-free survival, with a median of 17.7 months for the combination therapy versus 2 months for apalutamide alone. Consequently, the company modified the trial protocol to enroll patients earlier in disease progression and targets completion by the fourth quarter of 2027. Kairos Pharma is a clinical-stage biopharmaceutical company focused on oncology therapeutics that utilize structural biology to overcome drug resistance.
